{"id":"NCT00887978","sponsor":"United Therapeutics","briefTitle":"Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension","officialTitle":"A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2009-04-24","resultsPosted":"2013-01-15","lastUpdate":"2013-01-15"},"enrollment":310,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Hypertension"],"interventions":[{"type":"DRUG","name":"UT-15C SR","otherNames":["treprostinil diolamine, treprostinil diethanolamine, UT-15C"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"UT-15C SR","type":"EXPERIMENTAL"}],"summary":"This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). Study visits will occur at 4 week intervals for 16 weeks with the key measure of efficacy being the 6-minute walk test. Study procedures include routine blood tests, medical history, physical exams, disease evaluation, and exercise tests.\n\nPatients who complete all assessments for 16-weeks will also be eligible to enter an open-label, extension phase study (FREEDOM - EXT).","primaryOutcome":{"measure":"6-minute Walk Distance (6MWD)","timeFrame":"Baseline and 16 weeks","effectByArm":[{"arm":"UT-15C SR","deltaMin":370,"sd":null},{"arm":"Placebo","deltaMin":365,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.089"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":null},"locations":{"siteCount":62,"countries":["United States","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","Portugal","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["28090293","23669822"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":157},"commonTop":["Headache","Diarrhea","Nausea","Flushing","Pain in jaw"]}}